Severe acute respiratory syndrome coronavirus

eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent

Retrieved on: 
Thursday, July 22, 2021
Coronaviridae, Zoonoses, Animal diseases, Sarbecovirus, Antiviral drugs, Human coronavirus 229E, Severe acute respiratory syndrome coronavirus 2, Coronavirus, Coronavir, COVID-19, Middle East respiratory syndrome–related coronavirus, Severe acute respiratory syndrome coronavirus

The Phase 1b trial is a double-blind, randomized dose escalation trial in non-hospitalized patients ages 18-65 with mild to moderate COVID-19.

Key Points: 
  • The Phase 1b trial is a double-blind, randomized dose escalation trial in non-hospitalized patients ages 18-65 with mild to moderate COVID-19.
  • Further, in vitro studies have shown that zotatifin has potent antiviral activity across all unique coronavirus subtypes tested, including SARS-CoV-2, SARS-CoV-1, MERS-CoV and CoV-229E.
  • Zotatifin, eFFECTORs inhibitor of eIF4A, has recently completed the dose-escalation portion of a Phase 1/2 trial, and is now progressing into Phase 2a indication-specific expansion cohorts.
  • Neither LWAC nor eFFECTOR gives any assurance that either LWAC or eFFECTOR or the combined company will achieve its expectations.

Delta Variant Testing Device Developed by UAT Group Affiliate, Bacter Scientific

Retrieved on: 
Thursday, July 22, 2021
Coronaviridae, Sarbecovirus, Variants of SARS-CoV-2, COVID-19, Severe acute respiratory syndrome coronavirus 2, Zoonoses, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, COVID-20

Each new copy of a virus contains tiny copying errors or variations in its genome which is what is referred to as a variant.

Key Points: 
  • Each new copy of a virus contains tiny copying errors or variations in its genome which is what is referred to as a variant.
  • Novi is the only hand-held, portable, battery powered device with built-in redundancy, delivering the most accurate results of any testing device.
  • A US government SARS-CoV-2 Interagency Group (SIG) developed Variant Classifications that defines three classes of SARS-CoV-2 variants.
  • Bacter Scientific does not assume the obligation to update any forward-looking statement, except as required by applicable law.

ENZO BIOCHEM RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR RAPID EXTRACTION METHOD ON PROPRIETARY TEST SYSTEM FOR DETECTION OF CORONAVIRUS SARS-CoV-2

Retrieved on: 
Tuesday, July 20, 2021
Coronaviridae, Sarbecovirus, Zoonoses, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Assay, COVID-19, DiaSorin, Curative

The rapid extraction method can be used on platforms including Enzos proprietary GENFLEX automated high-throughput platform, Qiagens QIAsymphony SP lower-throughput platform and Enzos manual workflow.

Key Points: 
  • The rapid extraction method can be used on platforms including Enzos proprietary GENFLEX automated high-throughput platform, Qiagens QIAsymphony SP lower-throughput platform and Enzos manual workflow.
  • The AMPIPROBE SARS-Cov-2 Test System includes three components: sample collection, AMPIXTRACT SARS-CoV-2 Extraction Kit for sample processing, and AMPIPROBE SARS-CoV-2 Assay Kit for detection and analysis.
  • We are positioned to support rapid scale up and advance the new solutions in molecular testing that can address major challenges like COVID.
  • The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release.

Meissa Announces Preclinical Data on Intranasal COVID-19 Vaccine Showing Protection from SARS-CoV-2 Challenge after a Single Dose

Retrieved on: 
Tuesday, July 20, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Clinical trials, Clinical trials, COVID-19 vaccines, Coronaviridae, RNA vaccines, Medicine, Health sciences, COVID-19 vaccine, Medical research, Severe acute respiratory syndrome coronavirus, Rapid Deployment Vaccine Collaborative, ZF2001

The data demonstrate that a single adjuvant-free dose of MV-014-212 provided equivalent protection against SARS-CoV-2 challenge compared to reported efficacy in NHP models of currently authorized vaccines.

Key Points: 
  • The data demonstrate that a single adjuvant-free dose of MV-014-212 provided equivalent protection against SARS-CoV-2 challenge compared to reported efficacy in NHP models of currently authorized vaccines.
  • The data suggest a single, adjuvant-free, needle-free intranasal dose of MV-014-212 may provide broad immunity to protect against infection by SARS-CoV-2 and its variants.
  • In NHPs, Meissas intranasal COVID-19 vaccine generated both mucosal and systemic antibodies and was highly protective against wild-type SARS-CoV-2 challenge.
  • We believe Meissas intranasal COVID-19 vaccine has the potential to be an important part of the endgame solution to contain SARS-CoV-2.

US COVID-19 Surveillance Needs an Urgent Boost, Says AHF

Retrieved on: 
Tuesday, July 20, 2021
Infectious diseases, Genetics, Public policy, Government, Healthcare reform, White House, Federal Government, Health, State, Local, Public policy, Other Policy Issues, Coronaviridae, Sarbecovirus, Zoonoses, Bat virome, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Variant, SARS-CoV-2 Delta variant

New cases are up 129.3% from their lowest point on June 20, 2021, according to CDCs data on a seven-day moving average of recorded cases.

Key Points: 
  • New cases are up 129.3% from their lowest point on June 20, 2021, according to CDCs data on a seven-day moving average of recorded cases.
  • The most common strain of the virus is the highly infectious Delta variant, but the US is falling behind other developed countries in tracking and identifying new strains.
  • SARS-CoV-2 is highly prone to genetic variation as it replicates and spreads across different populations.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210719005833/en/

Selva to Present Preclinical Data at ASV 2021 Demonstrating Prophylactic and Therapeutic Oral Dosing of SLV213 for COVID-19 Protected Lungs from SARS-CoV-2-Induced Damage

Retrieved on: 
Monday, July 19, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Hospitals, Clinical trials, Medicine, Medical specialties, Clinical medicine, Sarbecovirus, Antiviral drugs, COVID-19 drug development, Immune system, Zoonoses, Monoclonal antibody, Remdesivir, Severe acute respiratory syndrome coronavirus

Additional in vitro data show that SLV213 greatly enhances the efficacy of remdesivir and molnupiravir, two drugs that target the virus.

Key Points: 
  • Additional in vitro data show that SLV213 greatly enhances the efficacy of remdesivir and molnupiravir, two drugs that target the virus.
  • These data will be presented at the 40th Annual Meeting of the American Society of Virology (ASV) taking place virtually July 19-23.
  • Similar to monoclonal antibodies, SLV-213 inhibits the activation of the spike protein required for SARS-CoV-2 to infect a cell.
  • At ASV 2021, Selva will present data showing SLV213 protected lungs against damage when given as a therapeutic or a prophylactic in a nonhuman primate (NHP) model, compared to untreated controls.

Hologic Obtains European CE Mark for Use of Saliva Samples with COVID-19 Test

Retrieved on: 
Wednesday, July 14, 2021
Science, Other Science, Biotechnology, General Health, Health, Medical devices, Infectious diseases, Genetics, Coronaviridae, Sarbecovirus, Zoonoses, Medical tests, Medical genetics, Bat virome, Hologic, Severe acute respiratory syndrome coronavirus, Molecular diagnostics, Severe acute respiratory syndrome, COVID-19

Hologic, Inc. (Nasdaq: HOLX) has obtained a CE Mark for the use of saliva samples with the Aptima SARS-CoV-2 assay in Europe.

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX) has obtained a CE Mark for the use of saliva samples with the Aptima SARS-CoV-2 assay in Europe.
  • The Aptima SARS-CoV-2 test is a molecular diagnostic assay that detects the genetic material of the pathogen causing COVID-19.
  • This new CE Mark demonstrates our commitment to providing European consumers and healthcare providers as many options as possible to manage the ongoing pandemic, said Jan Verstreken, Hologics group president, International.
  • Hologic, The Science of Sure, Aptima, and Panther are registered trademarks of Hologic, Inc. in the United States and/or other countries.

Genetron Health Receives CE Mark for 8-Gene Lung Cancer Assay and Provides FDA Reference Panel Comparative Data of its SARS-CoV-2 RNA Test

Retrieved on: 
Tuesday, July 13, 2021
Sarbecovirus, Zoonoses, Animal diseases, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Infectious diseases, Medicine

Separately, the Company also reported comparative data showing the sensitivity performance of the Genetron SARS-CoV-2 RNA Test.

Key Points: 
  • Separately, the Company also reported comparative data showing the sensitivity performance of the Genetron SARS-CoV-2 RNA Test.
  • The CE Mark represents the second regulatory milestone for 8-gene Lung Cancer Assay, as it is already approved by Chinas NMPA and is being commercialized in China.
  • We are excited to receive the CE Mark, which represents an important new commercialization opportunity for our 8-gene Lung Cancer Assay.
  • Separately, the Company also reported comparative performance data of its SARS-CoV-2 RNA Test based on a SARS-CoV-2 reference panel established by the U.S. Food and Drug Administration (FDA).

Eurofins Viracor Invests in Innovation with the Launch of Coronavirus (COVID-19) SARS-CoV-2 inSIGHT™ T Cell Immunity Testing

Retrieved on: 
Thursday, July 8, 2021
Coronaviridae, Medical specialties, Medicine, Eurofins Scientific, COVID-19 testing, COVID-19, Coronavir, Severe acute respiratory syndrome coronavirus

LEE'S SUMMIT, Mo., July 8, 2021 /PRNewswire/ --As one of the first commercial labs to deliver COVID-19 testing, Eurofins Viracor, Inc. continues to innovate with the launch of Coronavirus SARS-CoV-2 inSIGHT T Cell Immunity testing.

Key Points: 
  • LEE'S SUMMIT, Mo., July 8, 2021 /PRNewswire/ --As one of the first commercial labs to deliver COVID-19 testing, Eurofins Viracor, Inc. continues to innovate with the launch of Coronavirus SARS-CoV-2 inSIGHT T Cell Immunity testing.
  • Viracor's inSIGHT T Cell Immunity test delivers an understanding of a patient's response to viral antigens providing critical insight to aid in treatment decisions.
  • SARS-CoV-2 inSIGHT testing joins a robust menu of COVID-19 testing, including the recently-launched cPASS Coronavirus SARS-CoV-2 Neutralizing Antibody test.
  • Eurofins Viracor is a subsidiary of Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, and one of the world leaders in genomic services.

Inventive Health: COVID-19 Detected in 20 Seconds by Ultra-rapid Mouthwash or Nasal Swab Test Using Spectral Analysis Under MHRA Approval

Retrieved on: 
Thursday, July 8, 2021
Coronaviridae, Health sciences, Sarbecovirus, COVID-19, Occupational safety and health, Public health, Zoonoses, Nasopharyngeal swab, Mouthwash, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Swab

These signatures are interpreted using artificial intelligence as either positive or negative for SAR-Cov-2, the virus that causes COVID-19.

Key Points: 
  • These signatures are interpreted using artificial intelligence as either positive or negative for SAR-Cov-2, the virus that causes COVID-19.
  • Samples can be collected using either a nasopharyngeal swab or non-invasive mouthwash solution.
  • The MHRA approval process is being driven by Inventive Health and is currently focused on the nasopharyngeal swab with the mouthwash alternative following soon.
  • All pathogens such as SARS-CoV-2 have a unique high resolution digital signature that can be detected using spectral analysis.